Golden Biotechnology Corporation (UNQ: 4132)
Health Care · Biotechnology · TW
NT$—
— today · — 1Y
Golden Biotechnology Corporation (UNQ: 4132) operates in the Biotechnology industry within the Health Care sector.
trading between 3.47 and 36.30.
Tweenvest scores Golden Biotechnology Corporation across four factors: quality 17/100, value 41/100, growth 0/100. Its strongest factor is value.
4132 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $2.19M
- P/E
- —
- EPS
- -1.37
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- NT$36.30
- 52-week low
- NT$3.47
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 110
- Next earnings
- —
About Golden Biotechnology Corporation
Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, as well as hypercholesterolemia and hyperlipidemia. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- ISIN
- TW0004132006
- Founded
- 2002
- Listed since
- Jun 20, 2012
- Exchange
- Unquoted Security
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.